Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats.

CONCLUSIONS: Rosiglitazone successfully attenuates the development of CRAD via inhibition of TGF-β signaling, the renal tubular epithelial-to-mesenchymal transition (EMT), and inflammation. PMID: 30682409 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30682409?dopt=Abstract

Source: Transplant Immunology - January 22, 2019 Category: Transplant Surgery Authors: Deng J, Xia Y, Zhou Q, Wang X, Xiong C, Shao X, Shao M, Zou H Tags: Transpl Immunol Source Type: research